Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:AURANASDAQ:BGMNASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$4.55-4.0%$5.36$4.32▼$9.33$1.08B0.874.35 million shs8.79 million shsAURAAura Biosciences$5.43-4.9%$7.32$5.28▼$12.38$272.72M0.43196,532 shs564,873 shsBGMQilian International Holding Group$10.72-1.4%$10.25$5.26▼$14.78$1.04B1.3227,112 shs6,428 shsOCULOcular Therapeutix$6.36-9.1%$7.42$4.06▼$11.78$1.01B1.491.56 million shs2.89 million shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx-4.01%-7.71%-16.36%-8.45%-38.10%AURAAura Biosciences-4.90%-14.35%-27.50%-35.74%-25.62%BGMQilian International Holding Group-2.32%-5.55%+15.02%+14.41%+1,071,999,900.00%OCULOcular Therapeutix-9.14%-16.09%-11.05%-27.40%-24.73%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.1372 of 5 stars4.51.00.04.41.42.50.6AURAAura Biosciences1.9945 of 5 stars3.62.00.00.02.12.50.0BGMQilian International Holding GroupN/AN/AN/AN/AN/AN/AN/AN/AOCULOcular Therapeutix3.0926 of 5 stars3.40.00.04.12.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$10.61133.21% UpsideAURAAura Biosciences 3.25Buy$23.00323.57% UpsideBGMQilian International Holding Group 0.00N/AN/AN/AOCULOcular Therapeutix 2.88Moderate Buy$16.38157.47% UpsideCurrent Analyst Ratings BreakdownLatest AURA, ARDX, OCUL, and BGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025AURAAura BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/24/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/18/2025OCULOcular TherapeutixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$17.003/12/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold3/11/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.003/7/2025ARDXArdelyxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$15.003/7/2025ARDXArdelyxLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$11.003/4/2025OCULOcular TherapeutixJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/4/2025ARDXArdelyxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/4/2025ARDXArdelyxBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.003/4/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.62M3.25N/AN/A$0.73 per share6.23AURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/ABGMQilian International Holding Group$25.10M41.53N/AN/A$6.10 per share1.76OCULOcular Therapeutix$63.72M15.87N/AN/A$0.79 per share8.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.16N/A14.68N/A-11.73%-24.87%-10.51%5/1/2025 (Estimated)AURAAura Biosciences-$76.41M-$1.75N/AN/AN/AN/A-41.57%-36.43%5/8/2025 (Estimated)BGMQilian International Holding Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/AOCULOcular Therapeutix-$80.74M-$1.26N/AN/AN/A-283.74%-45.18%-30.87%5/6/2025 (Estimated)Latest AURA, ARDX, OCUL, and BGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025N/AARDXArdelyx-$0.10N/AN/AN/A$79.40 millionN/A3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/A3/3/2025Q4 2024OCULOcular Therapeutix-$0.24-$0.29-$0.05-$0.29$16.89 million$17.08 million2/20/2025Q4 2024ARDXArdelyx$0.02$0.02N/A$0.02$111.16 million$116.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AAURAAura BiosciencesN/AN/AN/AN/AN/ABGMQilian International Holding GroupN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx0.874.584.31AURAAura BiosciencesN/A12.4712.47BGMQilian International Holding GroupN/A3.392.82OCULOcular Therapeutix0.1913.0112.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%AURAAura Biosciences96.75%BGMQilian International Holding GroupN/AOCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipARDXArdelyx5.90%AURAAura Biosciences5.40%BGMQilian International Holding Group58.66%OCULOcular Therapeutix3.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90238.36 million222.88 millionOptionableAURAAura Biosciences5050.23 million47.25 millionNot OptionableBGMQilian International Holding Group29897.22 million2.48 millionN/AOCULOcular Therapeutix230159.02 million151.71 millionOptionableAURA, ARDX, OCUL, and BGM HeadlinesRecent News About These CompaniesNottingham Advisors Inc. Has $835,000 Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)April 5 at 5:56 AM | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Up 4.9% - Should You Buy?April 4 at 12:57 PM | marketbeat.comFinancial Analysis: Pacira BioSciences (NASDAQ:PCRX) versus Ocular Therapeutix (NASDAQ:OCUL)April 4 at 2:37 AM | americanbankingnews.comAnalysts Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) Price Target at $16.38April 4 at 1:45 AM | americanbankingnews.comOcular Therapeutix (NASDAQ:OCUL) Trading Down 5.8% - Time to Sell?April 3 at 12:59 PM | marketbeat.comRaymond James Financial Inc. Makes New $1.72 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)April 2 at 3:15 AM | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 2 at 2:14 AM | marketbeat.comOcular Therapeutix™ to Participate in Two Investor Conferences in AprilMarch 31, 2025 | globenewswire.comArtisan Partners Limited Partnership Purchases 278,610 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)March 30, 2025 | marketbeat.comOcular Therapeutix added to Analyst Current Favorites list at Raymond JamesMarch 27, 2025 | markets.businessinsider.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Raised by Rosalind Advisors Inc.March 23, 2025 | marketbeat.comVictory Capital Management Inc. Boosts Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)March 22, 2025 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Shares Gap Up - What's Next?March 19, 2025 | marketbeat.comRoyal Bank of Canada Begins Coverage on Ocular Therapeutix (NASDAQ:OCUL)March 19, 2025 | marketbeat.com3OCUL : What 4 Analyst Ratings Have To Say About Ocular TherapeutixMarch 18, 2025 | benzinga.comRBC Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform RecommendationMarch 18, 2025 | msn.comVIDEO: Dextenza saves time for ophthalmologists, increases efficiencyMarch 18, 2025 | healio.comOcular Therapeutix (OCUL) Gets a Buy from RBC CapitalMarch 18, 2025 | markets.businessinsider.comOcular Therapeutix initiated with an Outperform at RBC CapitalMarch 18, 2025 | markets.businessinsider.comWhy Ocular Therapeutix Was Bumping Higher This WeekMarch 14, 2025 | fool.comOcular Therapeutix (NASDAQ:OCUL) Shares Up 9.7% - Should You Buy?March 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingFirst Watch Restaurant Group: A First-Rate Small-Cap Growth StockBy Thomas Hughes | April 3, 2025View First Watch Restaurant Group: A First-Rate Small-Cap Growth StockAURA, ARDX, OCUL, and BGM Company DescriptionsArdelyx NASDAQ:ARDX$4.55 -0.19 (-4.01%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$4.63 +0.08 (+1.76%) As of 04/4/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Aura Biosciences NASDAQ:AURA$5.43 -0.28 (-4.90%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$5.20 -0.23 (-4.24%) As of 04/4/2025 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Qilian International Holding Group NASDAQ:BGM$10.72 -0.15 (-1.38%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$10.68 -0.04 (-0.37%) As of 04/4/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Ocular Therapeutix NASDAQ:OCUL$6.36 -0.64 (-9.14%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$6.60 +0.25 (+3.85%) As of 04/4/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/31 - 04/04 Conagra Stock Could Thrive as Tariffs Hit Other Sectors Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
